The effect of hematopoietic growth factors on neutrophil recovery after allogeneic transplantation is well-recognized. Recent laboratory studies demonstrated that these cytokines may also modify T-cell and dendritic cell function, but whether the effect is strong enough to alter the risk of GVHD is unclear. We performed a metaanalysis to determine the effect of G-CSF or GM-CSF on the risk of nonhematopoietic outcomes after allogeneic transplantation. A search of the literature from 1986 to present yielded 18 publications in which data were provided for cohorts receiving growth factor vs either placebo or no therapy. These included nine prospective randomized studies, eight retrospective cohort studies, and one case-control study comprising a total of 1198 patients. The publication types were heterogeneous with regard to demographic and treatment characteristics, although within publications, comparative groups were generally balanced. The pooled risk ratio estimates with use of growth factor was 1.08 (95% CI 0.87-1.33, P ¼ 0.48) for grades 2-4 acute GVHD, 1.22 (95% CI 0.80-1.86, P ¼ 0.99) for grades 3-4 acute GVHD, and 1.02 (95% CI 0.82-1.26, P ¼ 0.87) for chronic GVHD. This analysis did not detect a significant change in the risk of acute or chronic GVHD after allogeneic hematopoietic stem cell transplantation when hematopoietic growth factors were used to shorten the initial period of neutropenia. Bone Marrow Transplantation (2003) 32, 771-775. doi:10.1038/sj.bmt.1704228 Keywords: graft-vs-host disease; G-CSF; GM-CSF; allogeneic G-CSF and GM-CSF are hematopoietic cytokines active in the differentiation and proliferation of neutrophil progenitors as well as the regulation of mature neutrophil activity.
allogeneic G-CSF and GM-CSF are hematopoietic cytokines active in the differentiation and proliferation of neutrophil progenitors as well as the regulation of mature neutrophil activity.
Prospective clinical trials and retrospective cohort studies examining the safety and efficacy of these cytokines following allogeneic hematopoietic stem cell transplantation have variably demonstrated several beneficial effects, including reductions in time to hematopoietic recovery, transplant-related toxicity, duration of initial hospitalization, and resource utilization. As a result, judicious use of such growth factors is now considered routine at many allogeneic transplant centers.
The understanding of the secondary effects of G-CSF and GM-CSF, especially on the immune system, continues to evolve. In vitro studies of peripheral blood from healthy volunteers showed a Th2 polarization and anti-inflammatory profile in those treated with G-CSF, 23 while GM-CSF induced a profound proinflammatory response, 24 suggesting that when used for acceleration of neutrophil recovery after allogeneic transplantation, these cytokines might alter the risk of GVHD. Since most individual studies of cytokines for engraftment are not powered sufficiently to test for effects on GVHD, we performed a meta-analysis of the published data to determine whether the use of G-CSF and GM-CSF after allogeneic transplantation altered early nonhematopoietic outcomes.
Methods

Identification of studies and data abstraction
A Medline search was performed for the years 1986-2001 using combinations of the terms colony-stimulating factor, GM-CSF, G-CSF, allogeneic, transplant, marrow, and stem cell. Additional studies were sought by review of the abstracts from the annual meetings of the American Society of Hematology 1995-2000. These searches yielded 20 independent primary publications comparing outcomes in allogeneic marrow or blood stem cell transplant recipients with or without the use of GM-CSF or G-CSF for acceleration of hematopoietic recovery. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Of these, 18 reported cohorts using only a single colony-stimulating factor and provided information on grades 2-4 or 3-4 acute GVHD or on chronic GVHD. Data from review articles, duplicate publications, and autologous transplantation studies were excluded. Reports were also not included in the meta-analysis if comparative cohorts did not receive the same types of GVHD prophylaxis or if outcomes were not provided separately for GM-CSF and G-CSF. The publications were then reviewed by two of the coauthors for type of study, number of patients, patient age group, transplant cell source, donor histocompatibility, GVHD prophylaxis, hematopoietic growth factor used, hematopoietic recovery times, acute GVHD, chronic GVHD, days of fever, days of antibiotic use, time to discharge, and day-100 treatment-related mortality (TRM).
Statistical analyses
The risk ratios were calculated from the publication data on acute GVHD, chronic GVHD, and day-100 TRM for each individual study. The half-integer correction method was used when rates of zero were encountered. Homogeneity of the individual study estimates was tested using the Q statistic. If the null hypothesis of homogeneity was not rejected at the 0.05 significance level, a fixed effects model was used to compute a summary estimate of relative risk. In the absence of heterogeneity, the fixed effects model is equivalent to the random effects model in terms of the relative risk estimate and 95% confidence intervals. 25 If the null hypothesis of homogeneity was rejected (ie, the individual study estimates were heterogeneous), the data were examined for obvious outliers. The overall pooled estimates of the risk ratio with 95% confidence intervals were obtained for each outcome for all studies as well as when grouped by growth factor. Data are presented as forest plots of the individual studies and the summary risk ratio.
The presence of heterogeneity among studies was tested using the Q statistic and the Cochran X 2 value for (number of studies-1) degree of freedom. When the Q statisticderived X 2 P-value was less than 0.05, then heterogeneity among studies was considered to be present. The presence of heterogeneity means that the effect sizes (eg, relative risk) are unequal among the studies. The analyses were performed using Intercooled Stata version 7.0 (STATA Corporation, College Station, TX, USA).
The influence of publication bias on the reported outcome of acute GVHD, chronic GVHD, and day-100 TRM was tested by adjusted rank correlation and regression asymmetry tests according to methods of Begg and Mazumdar 26 and Egger et al. 27 The presence of publication bias means that there is a greater likelihood of a statistically significant study being published in comparison to one that demonstrates no statistical significance. Publication bias would occur if the published studies do not represent all studies that have been performed and would result in an inaccurate statistical inference.
Results
Publications included in the meta-analysis
A total of 19 comparisons with sufficient data were reported in 18 publications (Table 1) . Five were studies of GM-CSF and the remainder were of G-CSF. There were nine prospective randomized studies, eight retrospective cohort comparisons, and one case-control analysis com- prising a total of 1198 patients. The age group of the patients, patient-donor histocompatibility, cells used for transplantation, and GVHD prophylaxis varied among the studies (Table 1 ). Only three of the studies were performed using methotrexate-based GVHD prophylaxis for recipients of marrow from HLA-identical donors. The use of growth factor was associated with a significant reduction in time to recovery of neutrophil count 40.5 Â 10 9 /l in 18 of the 19 comparisons (Table 1) .
Acute GVHD
There were 17 comparisons for grades 2-4 acute GVHD (Figure 1a ) and 11 for grades 3-4 acute GVHD (Figure 1b) . Using the no growth factor cohort as the control, the pooled risk ratio estimate with use of growth factor was 1.08 (95% CI 0.87-1.33, P ¼ 0.48) for grades 2-4 acute GVHD and 1.22 (95% CI 0.80-1.86, P ¼ 0.99) for grades 3-4 acute GVHD. No significant effect was found when the meta-analysis was performed for each growth factor separately. For studies of G-CSF, the pooled risk ratio estimate was 1.01 (95% CI 0.79-1.29, P ¼ 0.92) for grades 2-4 acute GVHD and 1.31 (95% CI 0.77-2.22, P ¼ 0.99) for grades 3-4 acute GVHD. For studies of GM-CSF, the pooled risk ratio estimate was 1.22 (95% CI 0.85-1.75, P ¼ 0.27) for grades 2-4 acute GVHD and 1.08 (95% CI 0.54-2.17, P ¼ 0.81) for grades 3-4 acute GVHD.
Other transplant outcomes
There were eight comparisons for chronic GVHD ( Figure  1c) ; one study used GM-CSF and seven used G-CSF. The pooled risk ratio estimate was 1.02 (95% CI 0.82-1.26, P ¼ 0.87) for chronic GVHD. The heterogeneity test for these studies was significant (Q ¼ 16.411, P ¼ 0.02), so a summary effect estimate would be inaccurate. Excluding the two outlier studies reduced the heterogeneity and gave a pooled risk ratio estimate of 1.05 (95% CI 0.84-1.31, P ¼ 0.12). There were five comparisons for day-100 TRM, and all used G-CSF (Figure 1d ). The pooled risk ratio estimate was 0.70 (95% CI 0.38-1.31, P ¼ 0.28) for day-100 TRM.
Publication bias
To ascertain if there was publication bias among the various studies, Begg's funnel plots were generated. These showed no evidence of publication bias for studies reporting on grades 2-4 acute GVHD (Beggs' P ¼ 0.39, Egger's P ¼ 0.42), grades 3-4 acute GVHD (Beggs' P ¼ 0.16, Egger's P ¼ 0.33), chronic GVHD (Beggs' P ¼ 0.45, Egger's P ¼ 0.71), or day-100 TRM (Beggs' P ¼ 0.81, Egger's P ¼ 0.38).
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Discussion
A wealth of experimental evidence has led to the paradigm that acute GVHD is a Th1/Tc1-dominated response mediated by proinflammatory cytokines. 28 Thus, it was expected that drugs which induce a Th2-polarization, such as G-CSF, would reduce acute GVHD risk, and GM-CSF, which favors Th1-polarization, would have the opposite effect. Animal studies, however, have failed to confirm this hypothesis. In murine and canine models, administration of G-CSF for acceleration of engraftment either increased or did not alter the incidence of acute GVHD, and GM-CSF had no effect. [29] [30] [31] [32] In our meta-analysis of 18 clinical publications, we were also unable to detect an effect of either G-CSF or GM-CSF on the risk of acute GVHD.
Chronic GVHD, in contrast, is thought to be due to dysregulation of Th2 cells.
33 Th2-polarization induced by G-CSF might then exacerbate chronic GVHD. However, we did not find such an effect in this meta-analysis. Although the follow-up for patients in individual reports varied in duration and was sometimes quite short, this variability alone did not account for the lack of consistency in the risk of chronic GVHD with G-CSF, since the two publications with longest follow-up (5 and 3 years, respectively) had opposing conclusions regarding chronic GVHD. 11, 16 Our inability to detect a consistent effect of G-CSF or GM-CSF with regard to GVHD was probably not due to a lack of biological activity of these drugs, since nearly all studies demonstrated that the time to neutrophil recovery was in fact reduced by administration of growth factor. The secondary immunological effects might, however, be doseor schedule-dependent. For example, in liver transplant recipients, a short course of high-dose G-CSF was associated with a reduction in the incidence of acute rejection, 34 while a 21-day course of low-dose G-CSF resulted in an increase in biopsy-proved rejection. 35 Other variables that may have confounded the analysis include the type of GVHD prophylaxis, use of T-cell depletion, the degree on histoincompatibility between patient and donor, and whether the cytokine was glycosylated. In addition, the small, nonrandomized trials included in the analysis may not have had sufficient power to demonstrate a significant effect.
Our meta-analysis detected no significant effect of the hematopoietic cytokines on the risks of grades 2-4 or 3-4 acute GVHD, chronic GVHD, or early treatment-related mortality in this heterogeneous set of publications. The wide range of relative risks for each end point is consistent with the possibility that other variables (T-cell depletion, histoincompatibility, etc.) probably moderate the immunomodulatory effects of the cytokines. The present data, however, do not support the hypothesis that G-CSF or GM-CSF alters the risk of GVHD in any specific subset of patients.
